Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of treatments targeting unmet needs in infectious diseases in the United States and Canada. The company offers LIKMEZ (ATI-1501), a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial and protozoal infections. It also develops ATI-1801, a topical formulation of paromomycin in a Phase III trial for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine in preclinical trials for the prevention of Francisella tularensis infection. The company has a collaboration with Vitalex Biosciences to advance VXV-01, a dual-antigen vaccine targeting invasive Candida infections. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.
Frequently asked questions
What sector does Appili Therapeutics Inc (APLIF) operate in?
Appili Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Appili Therapeutics Inc (APLIF) current stock price?
As of the latest data, Appili Therapeutics Inc stock price is $0.01, with a previous close of $0.01.
What is Appili Therapeutics Inc (APLIF) current market capitalization?
Appili Therapeutics Inc market cap is approximately 926.56 thousand.
What is Appili Therapeutics Inc (APLIF) Earnings Per Share (EPS)?
The trailing EPS is -$0.02.
What is Appili Therapeutics Inc (APLIF) EBITDA?
Appili Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -1.14 million.
Does Appili Therapeutics Inc (APLIF) pay dividends?
No. Appili Therapeutics Inc does not pay a dividend.
What is Appili Therapeutics Inc (APLIF) beta (volatility) score?
Appili Therapeutics Inc has a beta of -0.190, indicating lower volatility than the overall market.
